Autonomix Medical abstracts on pancreatic cancer pain mitigation win EuroPCR 2026 acceptance
PUBT · 1d ago
Share
Listen to the news
- Autonomix Medical disclosed that two abstracts on its transvascular nerve-targeting device platform were accepted for presentation at EuroPCR 2026 in Paris on May 19-22, 2026.
- The presentations will cover long-term findings on pain mitigation in pancreatic cancer using the company’s denervation approach, alongside a separate overview of its precision-guided technology.
- The acceptance signals rising clinical interest in the platform, which Autonomix is positioning for broader use in conditions where nerve signaling drives symptoms.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autonomix Medical Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved